Labnesta - Company finances
|
EUR
|
2024
From: 2024-10-10
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|
|
Financial data
|
||
| Sales revenue | 42,272 | 780,205 |
| Profit before tax | 24,748 | 163,447 |
| Net profit | 24,748 | 137,170 |
| Equity | 29,748 | 103,669 |
| Liabilities | 52,126 | 126,380 |
| Non-current assets | 1,221 | 76,444 |
| Current assets | 80,653 | 151,081 |
| Total assets | 81,874 | 227,525 |
|
Taxes paid
|
||
| STI taxes | 4,056 | 141,132 |
|
Financial indicators
|
||
| Revenue change y/y | - | +1745.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 30.2% | 60.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 83.2% | 132.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 58.5% | 17.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 58.5% | 20.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.8 | 1.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 42,272 | 390,103 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Labnesta - Social security debts
The company had no debts to Sodra
Labnesta - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-07-07 | 2026-07-07 | 0.8 |
| 2026-01-01 | 2026-01-03 | 5.32 |
| 2025-10-03 | 2025-10-03 | 0.46 |
| 2025-07-01 | 2025-07-20 | 20.58 |
| 2025-07-15 | 2025-07-20 | 26.28 |
| 2025-06-30 | 2025-06-30 | 3.34 |
| 2025-06-11 | 2025-06-12 | 19.32 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Labnesta, UAB (code 307009147) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €780.2K and net profit of €137.2K, corresponding to a profit margin of 17.6%. This represents a sharp increase from 2024, when the company reported €42.3K in revenue and €24.7K in net profit over an 82-day period, indicating that 2025 was a substantially larger operating year. The balance sheet also expanded during 2025: total assets reached €227.5K, equity stood at €103.7K, and liabilities amounted to €126.4K. Long-term assets increased to €76.4K, while short-term assets were €151.1K. Key ratios point to strong operating efficiency, with asset turnover at 3.43x, ROA at 60.3%, and ROE at 132.3%, supported by revenue per employee of €390.1K and profit per employee of €68.6K. Overall, the 2025 results show a profitable and rapidly scaling business.